MA42231A - Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant - Google Patents

Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant

Info

Publication number: MA42231A
Authority: MA; Morocco
Prior art keywords: new; pharmaceutical compositions; preparation process; compositions containing; hydroxyacid derivatives
Prior art date: 2015-06-23

Application number

MA042231A

Other languages

English (en)

Other versions

MA42231B1 (fr

Inventor

Balázs Bálint

Maïa Chanrion

James Edward Paul Davidson

Olivier Geneste

András Kotschy

James Brooke Murray

Attila Paczal

Ágnes Proszenyák

Szabolcs Sipos

Zoltán Szlávik

Original Assignee

Servier Lab

Vernalis R&D Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-06-23

Filing date

2016-06-22

Publication date

2018-05-02

2016-06-22 Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab

2018-05-02 Publication of MA42231A publication Critical patent/MA42231A/fr

2023-04-28 Publication of MA42231B1 publication Critical patent/MA42231B1/fr

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Emergency Medicine (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Saccharide Compounds (AREA)

MA42231A 2015-06-23 2016-06-22 Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant MA42231B1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR1555753A FR3037958B1 (fr)	2015-06-23	2015-06-23	Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PCT/EP2016/064417 WO2016207216A1 (fr)	2015-06-23	2016-06-22	Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant

Publications (2)

Publication Number	Publication Date
MA42231A true MA42231A (fr)	2018-05-02
MA42231B1 MA42231B1 (fr)	2023-04-28

Family

ID=54260902

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA42231A MA42231B1 (fr)	2015-06-23	2016-06-22	Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant

Country Status (46)

Country	Link
US (1)	US10322131B2 (fr)
EP (1)	EP3313849B8 (fr)
JP (1)	JP6773695B2 (fr)
KR (1)	KR102620976B1 (fr)
CN (1)	CN107922432B (fr)
AR (1)	AR105104A1 (fr)
AU (1)	AU2016282827B2 (fr)
BR (1)	BR112017027831A2 (fr)
CA (1)	CA2990083C (fr)
CL (1)	CL2017003316A1 (fr)
CO (1)	CO2017012845A2 (fr)
CU (1)	CU20170162A7 (fr)
DK (1)	DK3313849T3 (fr)
DO (1)	DOP2017000304A (fr)
EA (1)	EA036503B1 (fr)
EC (1)	ECSP17082825A (fr)
ES (1)	ES2944942T3 (fr)
FI (1)	FI3313849T3 (fr)
FR (1)	FR3037958B1 (fr)
GE (1)	GEP20207076B (fr)
HK (2)	HK1250233A1 (fr)
HR (1)	HRP20230472T1 (fr)
HU (1)	HUE061758T2 (fr)
IL (1)	IL256320A (fr)
JO (1)	JO3807B1 (fr)
LT (1)	LT3313849T (fr)
MA (1)	MA42231B1 (fr)
MD (1)	MD3313849T2 (fr)
MX (1)	MX2017017008A (fr)
MY (1)	MY190243A (fr)
NZ (1)	NZ738469A (fr)
PE (1)	PE20180949A1 (fr)
PH (1)	PH12017502314A1 (fr)
PL (1)	PL3313849T3 (fr)
PT (1)	PT3313849T (fr)
RS (1)	RS64131B1 (fr)
RU (1)	RU2745430C9 (fr)
SA (1)	SA517390586B1 (fr)
SI (1)	SI3313849T1 (fr)
SV (1)	SV2017005590A (fr)
TN (1)	TN2017000529A1 (fr)
TW (2)	TW202108590A (fr)
UA (1)	UA124759C2 (fr)
UY (1)	UY36735A (fr)
WO (1)	WO2016207216A1 (fr)
ZA (1)	ZA201708626B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR3037956B1 (fr) *	2015-06-23	2017-08-04	Servier Lab	Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) *	2015-06-23	2017-08-04	Servier Lab	Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) *	2015-06-23	2019-01-25	Les Laboratoires Servier	Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) *	2015-06-23	2019-01-25	Les Laboratoires Servier	Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2017300738A1 (en)	2016-07-22	2019-02-07	Les Laboratoires Servier	Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof
EP3567043B1 (fr) *	2017-01-05	2023-12-06	Henan Genuine Biotech Co., Ltd.	Dérivés du acide propanoïque 2-[[5-[(4-hydroxy-3-chloro-2-méthyl)-phényl]-thiéno[2,3-d]pyrimidin-4-yl]oxy]-3-(2-méthoxybenzene) en tant qu'inhibiteurs mcl-1 et bcl-2 pour le traitement du cancer
EP3565547B1 (fr) *	2017-01-06	2024-03-13	Les Laboratoires Servier	Combinaison d'un inhibiteur de mcl-1 avec compose du taxane, utilisations et compositions pharmaceutiques associées
UY37560A (es) *	2017-01-06	2018-07-31	Servier Lab	Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
UY37777A (es)	2017-06-22	2019-01-31	Servier Lab	Combinación de un inhibidor de mcl-1 y un tratamiento de atención estándar para cánceres hematológico, usos y composiciones farmacéuticas de esta
BR112020003180A2 (pt)	2017-08-15	2020-09-15	AbbVie Deutschland GmbH & Co. KG	inibidores macrocíclicos de mcl-1 e métodos de uso
TW201920204A (zh) *	2017-08-15	2019-06-01	美商艾伯維有限公司	大環ｍｃｌ-１抑制劑以及使用方法
CN111372936B (zh) *	2017-11-23	2022-12-02	北京赛林泰医药技术有限公司	Mcl-1选择性抑制剂及其制备和用途
CN108424417B (zh) *	2017-12-21	2019-09-20	河南真实生物科技有限公司	噻吩并嘧啶衍生物、其制备方法及在制备抗肿瘤药物中的应用
AR116635A1 (es)	2018-10-15	2021-05-26	Servier Lab	Proceso para la síntesis de derivados de piperazinil-etoxi-bromofenilo y su aplicación en la producción de compuestos que los contienen
TWI849001B (zh)	2018-11-14	2024-07-21	法商施維雅藥廠	Mcl-1抑制劑及米哚妥林(midostaurin)之組合，其用途及醫藥組合物
AU2020279979A1 (en) *	2019-05-20	2021-11-25	Les Laboratoires Servier	Mcl-1 inhibitor antibody-drug conjugates and methods of use
AR119156A1 (es)	2019-06-17	2021-11-24	Servier Lab	Combinación de un inhibidor de mcl-1 y un tratamiento estándar de atención médica para cáncer de mama, usos y composiciones farmacéuticas de la misma
CN113024577B (zh) *	2019-12-09	2023-06-30	首药控股(北京)股份有限公司	一种抗凋亡蛋白选择性抑制剂的制备方法
IL303079A (en)	2020-11-24	2023-07-01	Novartis Ag	Antibody-drug conjugates inhibiting MCL-1 and methods of using them
AU2022290855A1 (en)	2021-06-11	2023-12-07	Gilead Sciences, Inc.	Combination mcl-1 inhibitors with anti-body drug conjugates
JP2024520801A (ja)	2021-06-11	2024-05-24	ギリアードサイエンシーズ，インコーポレイテッド	Ｍｃｌ－１阻害剤と抗がん剤との組み合わせ
AR129380A1 (es)	2022-05-20	2024-08-21	Novartis Ag	Conjugados de anticuerpo-fármaco de compuestos antineoplásicos y métodos de uso de los mismos

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070213305A1 (en) *	2005-11-02	2007-09-13	Cytovia, Inc.	N-alkyl-N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
EP2139869A2 (fr) *	2007-04-13	2010-01-06	SuperGen, Inc.	Inhibiteurs de la kinase axl utiles pour le traitement du cancer ou de maladies hyperprolifératives
CN102464667B (zh) *	2010-11-03	2014-06-04	中国科学院上海药物研究所	一类五元杂环并嘧啶类化合物及其制备方法和用途
AR090037A1 (es) *	2011-11-15	2014-10-15	Xention Ltd	Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
FR2986002B1 (fr) *	2012-01-24	2014-02-21	Servier Lab	Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3015483B1 (fr) *	2013-12-23	2016-01-01	Servier Lab	Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) *	2015-06-23	2019-01-25	Les Laboratoires Servier	Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) *	2015-06-23	2017-08-04	Servier Lab	Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) *	2015-06-23	2019-01-25	Les Laboratoires Servier	Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037956B1 (fr) *	2015-06-23	2017-08-04	Servier Lab	Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046792B1 (fr) *	2016-01-19	2018-02-02	Les Laboratoires Servier	Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

2015
- 2015-06-23 FR FR1555753A patent/FR3037958B1/fr active Active
2016
- 2016-06-16 UY UY0001036735A patent/UY36735A/es active IP Right Grant
- 2016-06-22 ES ES16731155T patent/ES2944942T3/es active Active
- 2016-06-22 GE GEAP201614680A patent/GEP20207076B/en unknown
- 2016-06-22 WO PCT/EP2016/064417 patent/WO2016207216A1/fr active Application Filing
- 2016-06-22 MX MX2017017008A patent/MX2017017008A/es unknown
- 2016-06-22 TN TNP/2017/000529A patent/TN2017000529A1/en unknown
- 2016-06-22 TW TW109118026A patent/TW202108590A/zh unknown
- 2016-06-22 MA MA42231A patent/MA42231B1/fr unknown
- 2016-06-22 LT LTEPPCT/EP2016/064417T patent/LT3313849T/lt unknown
- 2016-06-22 CA CA2990083A patent/CA2990083C/fr active Active
- 2016-06-22 BR BR112017027831A patent/BR112017027831A2/pt not_active Application Discontinuation
- 2016-06-22 PT PT167311554T patent/PT3313849T/pt unknown
- 2016-06-22 MD MDE20180439T patent/MD3313849T2/ro unknown
- 2016-06-22 CN CN201680048558.4A patent/CN107922432B/zh active Active
- 2016-06-22 RS RS20230299A patent/RS64131B1/sr unknown
- 2016-06-22 MY MYPI2017704890A patent/MY190243A/en unknown
- 2016-06-22 PL PL16731155.4T patent/PL3313849T3/pl unknown
- 2016-06-22 HU HUE16731155A patent/HUE061758T2/hu unknown
- 2016-06-22 EA EA201890124A patent/EA036503B1/ru unknown
- 2016-06-22 US US15/738,601 patent/US10322131B2/en active Active
- 2016-06-22 HR HRP20230472TT patent/HRP20230472T1/hr unknown
- 2016-06-22 CU CUP2017000162A patent/CU20170162A7/xx unknown
- 2016-06-22 DK DK16731155.4T patent/DK3313849T3/da active
- 2016-06-22 JO JOP/2016/0129A patent/JO3807B1/ar active
- 2016-06-22 KR KR1020187002026A patent/KR102620976B1/ko active IP Right Grant
- 2016-06-22 TW TW105119603A patent/TWI715593B/zh active
- 2016-06-22 PE PE2017002741A patent/PE20180949A1/es unknown
- 2016-06-22 SI SI201631700T patent/SI3313849T1/sl unknown
- 2016-06-22 RU RU2018102361A patent/RU2745430C9/ru active
- 2016-06-22 JP JP2017566288A patent/JP6773695B2/ja active Active
- 2016-06-22 FI FIEP16731155.4T patent/FI3313849T3/fi active
- 2016-06-22 AU AU2016282827A patent/AU2016282827B2/en active Active
- 2016-06-22 UA UAA201800619A patent/UA124759C2/uk unknown
- 2016-06-22 NZ NZ738469A patent/NZ738469A/en unknown
- 2016-06-22 EP EP16731155.4A patent/EP3313849B8/fr active Active
- 2016-06-23 AR ARP160101882A patent/AR105104A1/es active IP Right Grant
2017
- 2017-12-14 SV SV2017005590A patent/SV2017005590A/es unknown
- 2017-12-14 IL IL256320A patent/IL256320A/en active IP Right Grant
- 2017-12-14 PH PH12017502314A patent/PH12017502314A1/en unknown
- 2017-12-14 CO CONC2017/0012845A patent/CO2017012845A2/es unknown
- 2017-12-15 EC ECIEPI201782825A patent/ECSP17082825A/es unknown
- 2017-12-18 ZA ZA2017/08626A patent/ZA201708626B/en unknown
- 2017-12-20 DO DO2017000304A patent/DOP2017000304A/es unknown
- 2017-12-21 SA SA517390586A patent/SA517390586B1/ar unknown
- 2017-12-21 CL CL2017003316A patent/CL2017003316A1/es unknown
2018
- 2018-07-26 HK HK18109701.1A patent/HK1250233A1/zh unknown
- 2018-10-24 HK HK18113626.5A patent/HK1254477A1/zh unknown

Also Published As

Publication number	Publication date
EP3313849A1 (fr)	2018-05-02
KR20180015263A (ko)	2018-02-12
DK3313849T3 (da)	2023-05-30
CN107922432B (zh)	2021-05-04
HRP20230472T1 (hr)	2023-07-21
MY190243A (en)	2022-04-07
JP6773695B2 (ja)	2020-10-21
HK1254477A1 (zh)	2019-07-19
MX2017017008A (es)	2018-08-15
LT3313849T (lt)	2023-05-10
HK1250233A1 (zh)	2018-12-07
PT3313849T (pt)	2023-04-18
SI3313849T1 (sl)	2023-07-31
RS64131B1 (sr)	2023-05-31
KR102620976B1 (ko)	2024-01-05
NZ738469A (en)	2024-08-30
EA036503B1 (ru)	2020-11-17
EP3313849B8 (fr)	2023-05-10
RU2745430C1 (ru)	2021-03-25
GEP20207076B (en)	2020-03-10
RU2745430C9 (ru)	2021-06-28
MA42231B1 (fr)	2023-04-28
HUE061758T2 (hu)	2023-08-28
ES2944942T3 (es)	2023-06-27
EA201890124A1 (ru)	2018-05-31
WO2016207216A1 (fr)	2016-12-29
IL256320A (en)	2018-02-28
US10322131B2 (en)	2019-06-18
AU2016282827A1 (en)	2018-01-18
CA2990083A1 (fr)	2016-12-29
FR3037958A1 (fr)	2016-12-30
BR112017027831A2 (pt)	2018-09-04
MD3313849T2 (ro)	2023-07-31
PH12017502314B1 (en)	2018-06-25
EP3313849B1 (fr)	2023-02-22
CU20170162A7 (es)	2018-06-05
TW201712019A (zh)	2017-04-01
JO3807B1 (ar)	2021-01-31
TN2017000529A1 (en)	2019-04-12
US20180185369A1 (en)	2018-07-05
PH12017502314A1 (en)	2018-06-25
FR3037958B1 (fr)	2019-01-25
DOP2017000304A (es)	2018-02-28
AU2016282827B2 (en)	2020-07-09
CL2017003316A1 (es)	2018-04-27
FI3313849T3 (fi)	2023-05-11
SA517390586B1 (ar)	2022-02-20
UA124759C2 (uk)	2021-11-17
CO2017012845A2 (es)	2018-03-28
TWI715593B (zh)	2021-01-11
ECSP17082825A (es)	2018-02-28
CN107922432A (zh)	2018-04-17
PE20180949A1 (es)	2018-06-11
TW202108590A (zh)	2021-03-01
SV2017005590A (es)	2018-06-01
UY36735A (es)	2016-12-30
AR105104A1 (es)	2017-09-06
CA2990083C (fr)	2021-05-25
PL3313849T3 (pl)	2023-07-10
ZA201708626B (en)	2022-06-29
JP2018527296A (ja)	2018-09-20

Publication	Publication Date	Title
MA42231A (fr)	2018-05-02	Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant
FR3046792B1 (fr)	2018-02-02	Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr)	2017-08-04	Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3052452B1 (fr)	2018-06-22	Nouveaux derives de piperidinyle, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3015483B1 (fr)	2016-01-01	Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2986002B1 (fr)	2014-02-21	Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr)	2019-01-25	Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008979B1 (fr)	2015-07-24	Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MA37206B1 (fr)	2018-09-28	Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MA43172A (fr)	2018-09-12	Compositions pharmaceutiques et méthodes d'inhibition d'indolamine 2,3-dioxygénase et leurs indications
MX2023006541A (es)	2023-06-16	Formulaciones de dosis fija.
EA201791702A1 (ru)	2018-04-30	Терапевтические средства на основе гликанов и связанные с ними способы
FR3037956B1 (fr)	2017-08-04	Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP3349762A4 (fr)	2019-04-24	Co-cristaux d'inhibiteurs de sglt2, procédé pour leur préparation et compositions pharmaceutiques de ceux-ci
MA43835A (fr)	2018-11-28	Procédé de préparation de lieurs de médicaments pégylés et leurs intermédiaires
MA38803A1 (fr)	2017-10-31	Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
MA52118A (fr)	2021-05-19	Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose
FR2943342B1 (fr)	2011-03-04	Nouveaux derives de benzothiadiazepines,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
EA201500112A1 (ru)	2015-07-30	3-замещенные производные эстра-1,3,5(10),16-тетраена, способы их получения, фармацевтические средства, которые их содержат, и их использование для получения лекарственных средств
EA201691918A1 (ru)	2017-02-28	Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
MA50450A (fr)	2020-09-02	Nouveaux derives macrocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MA53900A (fr)	2022-01-26	Nouveaux dérivés d'amino-pyrimidonyl-pipéridinyl, leur procédé de préparation et compositions pharmaceutiques les contenant
IL262494A (en)	2018-12-31	A pharmaceutical combination preparation containing Ivacaptor and Lomaceptor complex compositions, their salts and derivatives, a process for their preparation and pharmaceutical preparations containing them
MA42264A (fr)	2018-05-02	Procédé de préparation d'oltipraz
MA43178A (fr)	2018-09-12	Analogues d'épothilone, procédés de synthèse, procédés de traitement, et conjugués médicamenteux de ceux-ci